文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺SABR后早期PSA密度动力学与长期生化复发生存

Post-SABR early PSA density kinetics in androgen deprivation therapy-naïve patients: early landmark models for long-term biochemical recurrence-free survival.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-17

本研究纳入294例接受45 Gy/5次SABR且未用ADT的前列腺癌患者,评估治疗后早期PSA密度动力学模型与7年生化复发生存(bRFS)的关系。结果显示,联合ISUP分级与早期PSA-D变化的复合模型可区分长期bRFS,且优于单一PSA-D阈值。

要点

  • 基线至3个月ΔPSA-D>0.138联合ISUP≥3可区分7年bRFS。
  • 3至6个月ΔPSA-D>0.033联合ISUP≥3亦与长期bRFS相关。
  • 早期PSA-D动力学模型优于单一PSA-D分类器。

核心结论

  • 前列腺SABR后早期PSA-D动力学可用于长期bRFS的早期风险分层。
  • 联合基线病理风险与早期PSA-D动力学的复合模型提供基于治疗反应的风险分层。

研究设计与样本

  • 前瞻性收集接受45 Gy/5次SABR且未用ADT的前列腺癌患者。
  • 采用预设的临床驱动landmark方法评估早期治疗后PSA-D变化。
  • 最终无ADT队列294例,发生39例生化复发。

主要发现

  • 7年bRFS在低危、 favorable intermediate-risk(FIR)、unfavorable intermediate-risk(UIR)和高危分别为100.0%、96.2%、83.4%和73.7%。
  • 基线至12个月PSA和PSA-D下降率在NCCN风险组间差异显著,UIR和高危下降更陡(均P < 0.001)。
  • 复发者从最早治疗后时间点PSA-D轨迹持续较高,3和6个月时分离更明显。
  • ISUP≥3联合ΔPSA-D(基线→3个月)>0.138,7年bRFS为96.7% vs 62.7%(P < 0.001)。
  • ISUP≥3联合ΔPSA-D(3→6个月)>0.033,7年bRFS为93.5% vs 53.4%(P < 0.001)。

关键数值与推荐

  • 基线锚定模型:ISUP≥3且ΔPSA-D(基线→3个月)>0.138。
  • 3→6个月模型:ISUP≥3且ΔPSA-D(3→6个月)>0.033。
  • 3特征复合评分固定时间区分度AUC为0.772。
  • Cox分析中ISUP≥3的HR为2.26(95% CI 1.17-4.40,P = 0.016)。
  • Cox分析中不良3→6个月PSA-D项的HR为3.41(95% CI 1.69-6.85,P < 0.001)。

临床怎么用

  • 对于接受SABR未用ADT的前列腺癌患者,可结合ISUP分级与早期PSA-D变化进行风险分层。
  • 复合动力学模型可补充基线NCCN分类,提供治疗反应层面的预后信息。

局限性

  • 3特征复合评分为探索性分析。
  • 固定时间7年ROC分析仅作描述性使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify early post-treatment prostate-specific antigen density (PSA-D) models associated with long-term biochemical recurrence-free survival (bRFS) after ultrahypofractionated prostate radiotherapy without androgen deprivation therapy (ADT), and to compare early kinetic composite models with single post-treatment PSA-D classifiers. METHODS AND MATERIALS: Prospectively collected patients receiving 45 Gy in 5 consecutive fractions without ADT were analyzed. This analysis used a prespecified, clinically driven landmark approach evaluating PSA-D change across early post-treatment intervals while prioritizing interpretability over model complexity. Candidate 2-factor models combined ISUP grade group with PSA-D kinetics in the baseline→3-month and 3 → 6-month windows and were screened by Kaplan-Meier separation, cohort size, and clinical usability, with fixed-time 7-year ROC analysis used descriptively. An exploratory 3-feature composite score was also assessed. RESULTS: The final no-ADT cohort comprised 294 patients with 39 biochemical relapses. Seven-year bRFS was 100.0%, 96.2%, 83.4%, and 73.7% for low-, favorable intermediate-risk (FIR), unfavorable intermediate-risk (UIR), and high-risk disease, respectively. PSA and PSA-D decline rates from baseline to 12 months differed significantly across NCCN risk groups, with steeper declines in UIR and high-risk disease than in FIR disease (both P < 0.001). Relapsing cases showed persistently higher PSA-D trajectories from the earliest post-treatment timepoints, with wider separation by 3 and 6 months. A baseline-anchored model, ISUP ≥3 plus ΔPSA-D(baseline→3 months) >0.138, separated 7-year bRFS at 96.7% versus 62.7% (P < 0.001). The 3 → 6-month model combining ISUP ≥3 plus ΔPSA-D(3 → 6 months) >0.033 separated 7-year bRFS at 93.5% versus 53.4% (P < 0.001). A 3-feature composite score showed the strongest fixed-time discrimination (AUC, 0.772). In Cox analysis, both ISUP ≥3 (HR, 2.26; 95% CI, 1.17-4.40; P = 0.016) and the adverse 3 → 6-month PSA-D term (HR, 3.41; 95% CI, 1.69-6.85; P < 0.001) remained independently associated with biochemical recurrence. Single PSA-D classifiers were predictive but less discriminative. CONCLUSIONS: Early PSA-D kinetics may support early risk stratification for long-term bRFS after prostate SABR without ADT. Composite models combining baseline pathologic risk with early PSA-D kinetics provide a treatment-response-based layer of risk stratification that complements baseline NCCN classification. Single PSA-D cutoffs remain informative but are less satisfactory than kinetic models because they do not capture response velocity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Greco C, Vieira B, Pares O, et al. Post-SABR early PSA density kinetics in androgen deprivation therapy-naïve patients: early landmark models for long-term biochemical recurrence-free survival. Clin Transl Radiat Oncol. 2026. PMID: 42662343. doi:10.1016/j.ctro.2026.101262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。